Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet).,Oral Oncology

当前位置： X-MOL 学术 › Oral Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet).
Oral Oncology ( IF 4.0 ) Pub Date : 2020-05-23 , DOI: 10.1016/j.oraloncology.2020.104766
Laura Locati ₁ , Stefano Cavalieri ₁ , Luigino Dal Maso ₂ , Susanna Busco ₃ , Lesley Ann Anderson ₄ , Laura Botta ₅ , Maria José Bento ₆ , Marià Carulla ₇ , Maria Dolores Chirlaque López ₈ , Mario Fusco ₉ , Marcela Guevara ₁₀ , Kaire Innos ₁₁ , Tom Børge Johannesen ₁₂ , Rita Micallef ₁₃ , Pamela Minicozzi ₁₄ , Chiara Panato ₂ , Dafina Petrova ₁₅ , Jordi Rubio-Casadevall ₁₆ , Giedre Smailyte ₁₇ , Maria Francesca Vitale ₉ , Annalisa Trama ₅ ,

Affiliation

Head and Neck Medical Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
UOC programmazione e controllo di gestione Asl Latina, Italy.
Northern Ireland Cancer Registry, Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
Evaluative Epidemiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
North Region Cancer Registry of Portugal (RORENO) & Cancer Epidemiology Group, IPO Porto Research Center (CI-IPOP), & Department of Population Studies, ICBAS, University of Porto, Portugal.
Tarragona Cancer Registry, Foundation Society for Cancer Research and Prevention, (FUNCA), Pere Virgili Health Research Institute (IISPV), Reus, Spain.
Department of Epidemiology Consejería de Salud, Región de Murcia / Murcia Regional Health Council Universidad de Murcia. IMIB-Arrixaca, CIBERESP, Spain.
Napoli 3 South Cancer Registry, Italy.
Public Health Institute of Navarre, Spain.
Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia.
Norwegian Cancer Registry, Norway.
Malta Cancer Registry: Health Information and Research. Department for Policy in Health, Malta.
Analytical Epidemiology and Health Impact Unit. Department of Predictive and Preventive Medicine, Fondazione IRCCS istituto Nazionale dei Tumori, Milan, Italy.
Granada Cancer Registry, Andalusian School of Public Health (EASP), Granada, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Universidad de Granada, Granada, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Epidemiology Unit and Girona Cancer Registry, Medical Oncology Department. Catalan Institute of Oncology, Girona, Spain.
Institute of Oncology, Vilnius University, Division of Cancer Prevention, Polocko 2, Vilnius, Lithuania.

Objective

Limited information is available on the incidence of rare thyroid cancer (TC) subtypes: anaplastic (ATC) and medullary (MTC). The aim of this study was to describe incidence variations and trends across European countries of all TC subtypes.

Materials and methods

We used the RARECAREnet database including 80721 TC incident cases in the period 2000–2007 from 77 population-based cancer registries (CRs) in Europe. In the trend analyses, we included 68890 TC cases from 53 CRs with at least 6 years of incidence data in the years 2000–2007.

Results

In Europe age-standardised incidence rates (ASR) in women were <0.3/100,000 for MTC and ATC whereas ASR were 5.3/100,000 for papillary thyroid cancer (PTC) and 1.1/100,000 for follicular TC (FTC). Corresponding ASRs in men were <0.2/100,000 for MTC and ATC, 1.5 for PTC and 0.4 for FTC. Across countries and in both sexes the incidence of FTC and MTC was moderately correlated (r ~ 0.5) with that of PTC, while a less marked correlation (r < 0.4) emerged for ATC ASRs. The changes of the PTC ASRs across countries and time were weakly (r < 0.3) or moderately (r ~ 0.5) correlated to the changes of the other subtypes for both sexes.

Conclusion

The huge increase and heterogeneity between countries of PTC incidence has a small influence on the trends and variations of MTC and ATC in Europe. Large-scale epidemiological and clinical registry-based studies are warranted to increase knowledge about the rarest TC subtypes. This information would be fundamental for the design of new clinical trials and for inference.

中文翻译：

欧洲罕见的甲状腺恶性肿瘤：来自欧洲罕见癌症信息网络的数据（RARECAREnet）。

目的

关于罕见的甲状腺癌（TC）亚型（间变性（ATC）和髓样（MTC））的发病率信息有限。这项研究的目的是描述欧洲所有TC亚型的发病率变化和趋势。

材料和方法

我们使用了RARECAREnet数据库，该数据库包括2000-2007年期间来自欧洲77个基于人口的癌症注册机构（CR）的80721 TC事件。在趋势分析中，我们纳入了2000-2007年来自53个CR的68890例TC病例，至少有6年的发病率数据。

结果

在欧洲，MTC和ATC的女性年龄标准化发病率（ASR）<0.3 / 100,000，而甲状腺乳头状癌（PTC）的ASR为5.3 / 100,000，而滤泡TC（FTC）的ASR为1.1 / 100,000。男性相应的ASR对于MTC和ATC分别为<0.2 / 100,000，对于PTC为1.5，对于FTC为0.4。在各个国家和地区，FTC和MTC的发生率与PTC呈中等程度的相关性（r〜0.5），而ATC ASR的相关性则较弱（r <0.4）。跨国家和时间的PTC ASR的变化与男女其他亚型的变化呈弱相关（r <0.3）或中等（r〜0.5）。